Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Northwest Biotherapeutics News

    0,4601 $ -2,54% -0,012 $
    In : 0,4301 € | 24.04.24 21:58:55 Nasdaq OTC Other aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A1J5EY
    ISIN: US66737P6007
    US-Symbol: NWBO
    Typ: Aktie

    Northwest Biotherapeutics News

    21.03.24 - PR Newswire
    Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors
    Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors PR Newswire
    06.02.24 - PR Newswire
    Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification
    Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-​Compliant Units For Installation, Validation and Final Testing Prior to Regulatory ...
    06.02.24 - PR Newswire
    Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification
    Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-​Compliant Units For Installation, Validation and Final Testing Prior to Regulatory ...
    21.12.23 - PR Newswire
    Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma
    Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma PR Newswire
    21.12.23 - PR Newswire
    Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma
    Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma PR Newswire
    22.11.23 - PR Newswire
    Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application
    Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application PR Newswire
    13.10.23 - PR Newswire
    Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application
    Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application PR Newswire
    13.10.23 - PR Newswire
    Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application
    Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application PR Newswire
    12.09.23 - PR Newswire
    Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board
    Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board PR Newswire
    12.09.23 - PR Newswire
    Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board
    Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board PR Newswire
    29.08.23 - PR Newswire
    Northwest Biotherapeutics Announces Completion of Prerequisites, and Plans for Submission of Marketing Authorization Application
    Northwest Biotherapeutics Announces Completion of Prerequisites, and Plans for Submission of Marketing Authorization Application PR Newswire
    29.08.23 - PR Newswire
    Northwest Biotherapeutics Announces Completion of Prerequisites, and Plans for Submission of Marketing Authorization Application
    Northwest Biotherapeutics Announces Completion of Prerequisites, and Plans for Submission of Marketing Authorization Application PR Newswire
    20.03.23 - PR Newswire
    Northwest Biotherapeutics and Advent BioServices Announce Receipt of License for Commercial Manufacturing at Sawston, U.K. Facility
    Northwest Biotherapeutics and Advent BioServices Announce Receipt of License for Commercial Manufacturing at Sawston, U.K. Facility PR Newswire
    20.03.23 - PR Newswire
    Northwest Biotherapeutics and Advent BioServices Announce Receipt of License for Commercial Manufacturing at Sawston, U.K. Facility
    Northwest Biotherapeutics and Advent BioServices Announce Receipt of License for Commercial Manufacturing at Sawston, U.K. Facility PR Newswire
    11.03.23 - PR Newswire
    Northwest Biotherapeutics Announces That It Has No Banking Relationship With SVB
    Northwest Biotherapeutics Announces That It Has No Banking Relationship With SVB PR Newswire
    06.01.23 - PR Newswire
    Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews 2022 Progress and Looks Forward to Strong 2023
    Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews 2022 Progress and Looks Forward to Strong 2023 PR Newswire
    06.01.23 - PR Newswire
    Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews 2022 Progress and Looks Forward to Strong 2023
    Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews 2022 Progress and Looks Forward to Strong 2023 PR Newswire
    17.11.22 - PR Newswire
    Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma
    Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma PR Newswire
    17.11.22 - PR Newswire
    Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma
    Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma PR Newswire
    23.08.22 - PR Newswire
    Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan (PIP) by MHRA
    Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan (PIP) by MHRA PR Newswire

    Newssuche

    Videos

    newspaper
    24.04.24
    Technical Trading: AUD/USD mit Mega Chance
    AUD/USD Long Typ: Turbo Open End WKN: UM0EHU Hebel: 6,42 Laufzeit: OpenEnd Einstieg: Market ... Mehr »